DoD Rare Cancers, Resource and Community Development Award | W81XWH 22 RCRP RCDA

Opportunity Information: Apply for W81XWH 22 RCRP RCDA

The DoD Rare Cancers, Resource and Community Development Award (FY22 RCRP RCDA; Funding Opportunity Number W81XWH-22-RCRP-RCDA) is a Department of Defense research funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that focuses on building shared resources and strengthening community infrastructure for rare cancers. Rather than funding a single narrowly defined biology project, the program is aimed at solving practical, field-wide bottlenecks that slow progress in rare cancer research and patient care. The overall purpose is to develop resource platforms that make it easier for researchers, clinicians, patients, caregivers, and advocates to find, share, and use rare cancer data, models, and knowledge in ways that ultimately improve outcomes.

The opportunity is grounded in several persistent gaps commonly seen across rare cancers: limited communication and dissemination of research and clinical findings within rare cancer communities; too few therapeutics and mechanistic studies to guide treatment development; inadequate research and clinical resources such as patient tissues and well-characterized cell and tumor models; and a lack of infrastructure for sharing data and other critical resources. In practice, rare cancers often suffer from fragmented data, small patient cohorts spread across institutions, inconsistent data standards, and limited access to biospecimens or validated models. This award is designed to address those issues by supporting platforms that organize and connect what is already known and what is being generated, so that progress is not repeatedly slowed by reinvention, siloed datasets, or inaccessible materials.

A central expectation is that proposed projects will create or expand platforms that share resources and knowledge related to available models, molecular pathways, and therapeutic approaches. The solicitation gives representative examples of what counts as a “platform” for this award. These include building and sharing a rare tumor biospecimen repository with strong clinical annotation; creating databases or data banks that centralize and share patient registry data in a way that can be accessed globally; centralizing and sharing research models and molecular datasets spanning genomics, transcriptomics, immune profiling, proteomics, metabolomics, methylomics, and bioinformatics; developing a data/reagent/model exchange program where researchers can list sharable resources and tag them by potentially relevant indications; enabling or leveraging longitudinal studies that track natural history and treatment response over time; and developing new methods and systems for collecting, sharing, and analyzing data or biospecimens. The common thread across these examples is interoperability and broad utility: tools and infrastructures that reduce friction, increase reuse, and help multiple stakeholders collaborate more efficiently.

Applications are expected to present a well-constructed project design backed by a strong scientific rationale, with a clear explanation of the unmet need being addressed in rare cancer research. The program also pushes applicants to justify why their approach is better than standard methods, whether that advantage comes from improved accessibility, stronger data standards, better governance, more scalable sharing mechanisms, more meaningful clinical annotation, or more effective community engagement. Just as important, applicants must lay out a concrete collaboration and data-sharing plan, since the value of these awards depends heavily on whether the resulting resources can be widely used rather than remaining confined to a single lab, institution, or network.

A defining requirement is that the outcomes should benefit multiple rare cancers, not just one niche disease. This multi-disease emphasis reflects the reality that many rare cancers face similar barriers (small sample sizes, limited models, scattered expertise), and that shared infrastructure can often accelerate progress across several indications at once. In other words, the strongest fit for this award is a project that builds something durable and broadly usable, such as a repository, registry backbone, exchange system, or integrated data/model platform that allows the rare cancer field to collaborate faster and with fewer barriers.

Administratively, the opportunity is categorized as discretionary funding, using grant and cooperative agreement mechanisms, under CFDA 12.420 (Science and Technology and other Research and Development). Eligibility is listed as unrestricted, meaning it is broadly open to different entity types, subject to any additional eligibility clarifications in the full notice. The posting shows an anticipated total of four awards, with an award ceiling listed as 0 in the source record (typically meaning the ceiling was not specified in that particular summary field rather than implying no limit). The opportunity was created April 20, 2022, with an original closing date of September 30, 2022.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Rare Cancers, Resource and Community Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 20, 2022.
• Applicants must submit their applications by Sep 30, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 RCRP RCDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: